Product image of Levonorgestrel/Etinilestradiol Diario Durban (Ethinylestradiol, Levonorgestrel | Lactose) supplied by GNH India

Levonorgestrel/Etinilestradiol Diario Durban

Active Ingredient:
Ethinylestradiol, Levonorgestrel | Lactose
Origin:
EU

Levonorgestrel/Etinilestradiol Diario Durban (Ethinylestradiol, Levonorgestrel | Lactose)

Ethinylestradiol, the active ingredient in Levonorgestrel/Etinilestradiol Diario Durban, is a combined oral contraceptive presented as a tablet for oral use. It is indicated for preventing pregnancy in women of reproductive age.
GNH India supplies Levonorgestrel/Etinilestradiol Diario Durban as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratorios Francisco Durbán S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Levonorgestrel/Etinilestradiol Diario Durban, a combined oral contraceptive, is used within the hormonal contraception pathway.
  • Contraception: Prevents pregnancy by inhibiting ovulation and altering cervical mucus.
  • Menstrual cycle regulation: Helps establish regular menstrual bleeding patterns.
  • Dysmenorrhea management: Reduces the severity of painful menstrual cramps.

How It Works

  • Ethinylestradiol and levonorgestrel act together to suppress the mid‑cycle surge of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), thereby preventing ovulation. The estrogen component stabilises the endometrial lining, while the progestogen component thickens cervical mucus and induces endometrial changes that reduce the likelihood of implantation.

Side Effects

Levonorgestrel/Etinilestradiol Diario Durban may cause a range of adverse reactions.

Common Side Effects

  • Nausea or mild stomach upset.
  • Breast tenderness or enlargement.
  • Headache or migraine.
  • Spotting or breakthrough bleeding.
  • Mood swings or mild depression.
  • Weight fluctuation.

Serious or Rare Side Effects

  • Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism.
  • Severe hypertension or cardiovascular complications.
  • Liver dysfunction or cholestatic jaundice.
  • Anaphylactic or severe allergic reactions.
  • Visual disturbances or ocular migraines.
  • Gallbladder disease, including cholelithiasis.

Precautions & Warnings

  • Before prescribing Levonorgestrel/Etinilestradiol Diario Durban, clinicians should consider several safety aspects.
  • Medical history review: Assess for clotting disorders, cardiovascular disease, liver disease, and smoking status.
  • Contraindications: Avoid use in known pregnancy, thrombophilia, uncontrolled hypertension, or active liver disease.
  • Drug interaction check: Evaluate concomitant medications that may induce hepatic enzymes or affect coagulation.
  • Monitoring: Periodic blood pressure and lipid profile assessments are recommended.
  • Store at ambient temperature: Keep below 25°C in the original packaging, protect from moisture.

Avoid Interactions

Levonorgestrel/Etinilestradiol Diario Durban can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce contraceptive efficacy.
  • Concurrent anticoagulants (e.g., warfarin) can increase thrombosis risk.
  • Certain antiretrovirals (e.g., protease inhibitors) may alter hormone levels.

Moderate Interactions (Monitor Closely)

  • Selective serotonin reuptake inhibitors may heighten mood‑related side effects.
  • Antihypertensive agents may require blood‑pressure monitoring when combined.
  • Herbal supplements such as St. John’s wort can modestly decrease effectiveness.

Frequently Asked Questions

Levonorgestrel/Etinilestradiol Diario Durban is a combined oral contraceptive tablet used to prevent pregnancy in women of reproductive age. It works by inhibiting ovulation and creating cervical mucus changes that reduce the chance of fertilisation and implantation.

Ethinylestradiol, the estrogen component, stabilises the endometrial lining and contributes to the suppression of the luteinising hormone surge. Together with levonorgestrel, it prevents the release of an egg and modifies cervical mucus, providing effective contraception.

The specific dosing regimen for Levonorgestrel/Etinilestradiol Diario Durban is determined by the prescribing healthcare professional. The prescriber will select the appropriate tablet strength, frequency and duration based on individual patient needs and clinical guidelines.

Levonorgestrel/Etinilestradiol Diario Durban is contraindicated during pregnancy because it is intended to prevent conception. Use while breastfeeding should be discussed with a healthcare provider, as hormonal contraceptives may affect milk production and infant exposure.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levonorgestrel/Etinilestradiol Diario Durban contains the widely used estrogen‑progestogen pair of ethinylestradiol and levonorgestrel, offering a balance of efficacy and tolerability comparable to other second‑generation combined pills. Differences among products typically relate to hormone dose, tablet formulation and specific brand‑related excipients.

Store Levonorgestrel/Etinilestradiol Diario Durban at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

The medication is taken orally, usually once daily at the same time each day, as directed by the prescriber. Tablets should be swallowed whole with water and not chewed or broken, unless specific instructions are provided.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe hypertension, liver disorders, and rare allergic reactions. Patients should seek immediate medical attention if they experience unexplained leg pain, shortness of breath, severe headache, jaundice or signs of an allergic reaction.

Women with a known history of clotting disorders, active or past thromboembolic disease, uncontrolled hypertension, certain liver diseases, current pregnancy, or those who smoke heavily and are over 35 years old should avoid this product. A thorough medical assessment is essential before initiation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Levonorgestrel | Lactose

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT